Document Detail


Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.
MedLine Citation:
PMID:  16377673     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Zygomycetes are emerging opportunistic molds resistant to most conventional antifungals. We evaluated the in vitro activity of lovastatin (LOV), a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, against seven clinical isolates of Zygomycetes by using standard microdilution methods in three different media, disk diffusion testing, and viability dye staining. To further study the in vivo efficacy of LOV against zygomycetes, we developed a Drosophila melanogaster model of zygomycosis. In different experiments, groups of Toll-deficient (Tl) flies fed LOV-containing food were subsequently injected with two representative Zygomycetes isolates (Mucor and Rhizopus spp.). Finally, we examined the effects of LOV on voriconazole (VRC) activity against zygomycetes in vitro by checkerboard dilution, Epsilometer test-based methods, and bis-(1,3-dibutylbarbituric acid) trimethine oxonol staining and in vivo in Tl flies fed food containing LOV plus VRC and infected with zygomycetes. LOV exhibited significant, medium, and strain-independent fungicidal activity against all Zygomycetes isolates in vitro by all testing methods (MIC50, 48.0 microg/ml; 50% minimal fungicidal concentration, 56.0 microg/ml; 50% effective concentration, 29.4 microg/ml [6.6 to 38.9 microg/ml]). Tl flies fed LOV-containing food and infected with Mucor had a significantly better 6-day survival rate than did infected Tl flies fed regular food (P = 0.0005). LOV displayed in vitro synergy with VRC against all Zygomycetes isolates (fractional inhibitory concentration index, 0.104 to 0.290) by all methods used. LOV also displayed synergy with VRC in the Drosophila model of zygomycosis (P < 0.01). LOV is significantly active against zygomycetes and synergizes with triazoles inherently resistant to them, such as VRC. The clinical significance of these findings needs to be further explored.
Authors:
Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Related Documents :
15698693 - Effectiveness of household natural sanitizers in the elimination of salmonella typhimur...
11971783 - Salmonella enterica serotype enteritidis phage type 4b outbreak associated with bean sp...
17801153 - Stimulation of food species growth by limpet mucus.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  50     ISSN:  0066-4804     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-26     Completed Date:  2006-03-31     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  96-103     Citation Subset:  IM    
Affiliation:
Department of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antifungal Agents / pharmacology*
Drug Synergism*
Fungi / drug effects*,  isolation & purification
Lovastatin / pharmacology*
Microbial Sensitivity Tests / methods
Mycoses / microbiology
Pyrimidines / pharmacology*
Triazoles / pharmacology*
Chemical
Reg. No./Substance:
0/Antifungal Agents; 0/Pyrimidines; 0/Triazoles; 0/voriconazole; 75330-75-5/Lovastatin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and ...
Next Document:  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacteri...